Ensysce Biosciences, Inc.
ENSC · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $14,221 | $35,998 | $24,291 | $1,421,585 |
| - Cash | $3,502 | $1,124 | $3,148 | $12,265 |
| + Debt | $302 | $855 | $4,434 | $17,214 |
| Enterprise Value | $11,020 | $35,729 | $25,577 | $1,426,534 |
| Revenue | $5,210 | $2,231 | $2,523 | $3,531 |
| % Growth | 133.5% | -11.6% | -28.5% | – |
| Gross Profit | -$2,009 | -$5,357 | -$17,312 | $3,531 |
| % Margin | -38.6% | -240.1% | -686.1% | 100% |
| EBITDA | -$6,730 | -$10,718 | -$24,222 | -$25,930 |
| % Margin | -129.2% | -480.4% | -959.9% | -734.3% |
| Net Income | -$7,987 | -$10,613 | -$24,172 | -$29,084 |
| % Margin | -153.3% | -475.7% | -957.9% | -823.6% |
| EPS Diluted | -4.57 | -4.69 | -139.44 | -355.68 |
| % Growth | 2.6% | 96.6% | 60.8% | – |
| Operating Cash Flow | -$7,502,700,000 | -$10,780 | -$17,887 | -$8,242 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | -$7,502,700,000 | -$10,780 | -$17,887 | -$8,242 |